Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
lamivudine, raltegravir potassium
Merck Sharp Dohme Limited
J05AR16
lamivudine, raltegravir potassium
Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations
HIV Infections
Dutrebis is indicated in combination with other anti‑retroviral medicinal products for the treatment of human immunodeficiency virus (HIV‑1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).
Withdrawn
2015-03-26
38 B. PACKAGE LEAFLET Medicinal product no longer authorised 39 PACKAGE LEAFLET: INFORMATION FOR THE USER DUTREBIS 150 MG/300 MG FILM-COATED TABLETS lamivudine/raltegravir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. IF YOU ARE THE PARENT OF A CHILD TAKING DUTREBIS, PLEASE READ THIS INFORMATION CAREFULLY WITH YOUR CHILD. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you or your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What DUTREBIS is and what it is used for 2. What you need to know before you take DUTREBIS 3. How to take DUTREBIS 4. Possible side effects 5. How to store DUTREBIS 6. Contents of the pack and other information 1. WHAT DUTREBIS IS AND WHAT IT IS USED FOR WHAT DUTREBIS IS DUTREBIS is an antiretroviral medicine used to treat infection with human immunodeficiency virus (HIV). It contains the active substances lamivudine and raltegravir: Lamivudine belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs) Raltegravir belongs to a group of medicines called HIV integrase strand transfer inhibitors WHAT DUTREBIS IS USED FOR DUTREBIS is used to treat HIV (Human Immunodeficiency Virus). HIV is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). DUTREBIS is used in combination with other medicines to treat adults, adolescents, and children 6 years of age and older and weighing at least 30 kg who are infected by HIV. Your doctor has prescribed DUTREBIS to help control your HIV infection. HOW DUTREBIS WORKS When used with other medicines, DUTREBIS may: reduce the amount of HIV in your blood Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT DUTREBIS 150 mg/300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg of lamivudine and 300 mg of raltegravir (as potassium). Excipient with known effect: Each tablet contains 39.70 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Green, oval tablet, marked with "144" on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DUTREBIS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Therapy should be initiated by a physician experienced in the management of HIV infection. Posology DUTREBIS should be used in combination with other active anti-retroviral therapy (ART) (see sections 4.4 and 5.1). _Adults, adolescents, and children (6 through 11 years of age weighing at least 30 kg)_ The recommended dosage is one tablet (150 mg lamivudine/300 mg raltegravir) twice daily. Raltegravir is also available in a chewable tablet formulation for children weighing at least 11 kg and in granules for oral suspension formulation for infants and toddlers from 4 weeks of age and weighing at least 3 kg to less than 20 kg. Refer to the chewable tablet and granules for oral suspension SmPCs for additional dosing information. Lamivudine is also available as an oral solution for children over three months of age and who weigh less than 14 kg or for patients who are unable to swallow tablets. The maximum dose is one tablet twice daily. _Advice on missed Przeczytaj cały dokument